Study Subject Participation Status | Investigational New Drugs
Item
patient completed study cldt600acn04 study and will be available to immediately rollover into this study without discontinuation of study drug.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Absence Patient withdrawn from trial
Item
patient was not discontinued from the previous cldt600acn04 study.
boolean
C0332197 (UMLS CUI [1,1])
C0422727 (UMLS CUI [1,2])
Hepatitis B, Chronic | Hepatitis B e antigen positive | Hepatitis B e antigen negative
Item
adult patients with chb (hbeag positive or hbeag negative).
boolean
C0524909 (UMLS CUI [1])
C0392390 (UMLS CUI [2])
C0948827 (UMLS CUI [3])
Hbv DNA Test PCR Negative
Item
hbv dna pcr undetectable in recent 12 months.
boolean
C1256114 (UMLS CUI [1,1])
C0032520 (UMLS CUI [1,2])
C1513916 (UMLS CUI [1,3])
Pregnancy | Breast Feeding | Pregnancy, Planned
Item
pregnant or breastfeeding, or has plan of pregnant during study period.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
HCV coinfection | Coinfection Hepatitis Delta Virus | HIV coinfection
Item
patient is co-infected with hepatitis c virus (hcv), hepatitis d virus (hdv), or hiv at screening visit.
boolean
C1698259 (UMLS CUI [1])
C0275524 (UMLS CUI [2,1])
C0011220 (UMLS CUI [2,2])
C4062778 (UMLS CUI [3])
Combined Modality Therapy Anti-hepatitis B (HBV) Agents | telbivudine
Item
patient has received within the past 12 months any anti-hbv treatment combination (add-on therapy) or switch to other anti hbv treatment from telbivudine at investigator's discretion.
boolean
C0009429 (UMLS CUI [1,1])
C4020577 (UMLS CUI [1,2])
C1453933 (UMLS CUI [2])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])